We are live on
!
Find out more
PA
Perceptive Advisors Portfolio holdings
AUM
$6.66B
1-Year Est. Return
360.84%
This Fund
S&P 500
This Quarter
Est. Return
+13.47%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$3.57B
AUM Growth
+$553M
(+18%)
Cap. Flow
+$561M
Cap. Flow
% of AUM
15.73%
Top 10 Holdings %
Top 10 Hldgs %
49.57%
Holding
170
New
38
Increased
32
Reduced
29
Closed
33
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$104M |
| 2 |
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
+$79.7M |
| 3 |
Ascendis Pharma A/S
ASND
|
+$55.2M |
| 4 |
YARW
Yarrow Bioscience
YARW
|
+$54M |
| 5 |
FOLD
Amicus Therapeutics
FOLD
|
+$32.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AnaptysBio
ANAB
|
+$58.5M |
| 2 |
Neurocrine Biosciences
NBIX
|
+$32.9M |
| 3 |
Intuitive Surgical
ISRG
|
+$25.4M |
| 4 |
AVXS
AveXis, Inc. Common Stock
AVXS
|
+$24.2M |
| 5 |
Zimmer Biomet
ZBH
|
+$24.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 97.46% |
| 2 | Consumer Staples | 0.67% |
| 3 | Consumer Discretionary | 0.06% |
| 4 | Industrials | 0.02% |
| 5 | Technology | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ADMS
51
DELISTED
Adamas Pharmaceuticals
ADMS
| $15.1M | 0.42% |
+630,000
| New | +$19.9M |
|
|
PTLA
52
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
| $14.4M | 0.4% |
+440,000
| New | +$19.3M |
|
53
Abeona Therapeutics
ABEO
$355M
| $14.2M | 0.4% |
39,926
+37,540
| +1,573% | +$13.9M |
|
|
MOTS
54
DELISTED
Motus GI Holdings, Inc. Common Stock
MOTS
| $12.6M | 0.35% |
+9,368
| New | +$13.2M |
|
|
ABEOW
55
DELISTED
Abeona Therapeutics Inc Warrant
ABEOW
| $12M | 0.34% |
1,259,636
| – | – |
|
56
Rhythm Pharmaceuticals
RYTM
$7.8B
| $11.8M | 0.33% |
592,286
-152,849
| -21% | -$4.06M |
|
57
Teleflex
TFX
$5.94B
| $10.4M | 0.29% |
40,900
-85,000
| -68% | -$22.3M |
|
|
SRRA
58
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
| $10.3M | 0.29% |
125,000
| – | – |
|
|
CLLS
59
Cellectis
CLLS
$344M
| $9.45M | 0.26% |
300,000
-50,000
| -14% | -$1.58M |
|
|
AVDL
60
DELISTED
Avadel Pharmaceuticals
AVDL
| $9.45M | 0.26% |
1,295,841
-1,096,000
| -46% | -$9.64M |
|
|
AGRX
61
DELISTED
Agile Therapeutics
AGRX
| $9.07M | 0.25% |
1,765
+75
| +4% | +$496K |
|
|
SYBX
62
DELISTED
Synlogic
SYBX
| $8.84M | 0.25% |
62,857
+17,100
| +37% | +$2.65M |
|
|
NVTA
63
DELISTED
Invitae Corporation
NVTA
| $8.7M | 0.24% |
1,851,100
-153,400
| -8% | -$1.09M |
|
|
OMED
64
DELISTED
OncoMed Pharmaceuticals, Inc.
OMED
| $8.33M | 0.23% |
2,620,897
| – | – |
|
65
CareDx
CDNA
$2.63B
| $8.29M | 0.23% |
1,040,676
| – | – |
|
66
PTC Therapeutics
PTCT
$6.13B
| $8.12M | 0.23% |
+300,000
| New | +$7.6M |
|
67
Zymeworks
ZYME
$1.96B
| $7.78M | 0.22% |
693,890
-83,607
| -11% | -$904K |
|
|
CLSD
68
DELISTED
Clearside Biomedical
CLSD
| $7.68M | 0.22% |
47,679
+6,334
| +15% | +$772K |
|
|
AVEO
69
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
| $7.13M | 0.2% |
245,812
-50,000
| -17% | -$1.46M |
|
70
CALL
Incyte
INCY
$26.3B
| $6.95M | 0.19% |
+1,510,000
| New | +$136M |
|
|
FLXN
71
DELISTED
Flexion Therapeutics, Inc.
FLXN
| $6.9M | 0.19% |
307,989
| – | – |
|
|
ARNA
72
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $6.79M | 0.19% |
171,978
+150,000
| +683% | +$5.83M |
|
73
Acadia Pharmaceuticals
ACAD
$5.27B
| $6.18M | 0.17% |
+275,000
| New | +$7.61M |
|
74
Ocugen
OCGN
$475M
| $6.06M | 0.17% |
36,721
+7,091
| +24% | +$1.13M |
|
75
Cartesian Therapeutics
RNAC
$314M
| $6.05M | 0.17% |
19,792
-1,298
| -6% | -$370K |
|
Similar funds
QP
FCBT
RWM
AWA
WHRC
LSERS
CAG
MCM
Perceptive Advisors's Q1 2018 Portfolio in Review
As of Q1 2018, Perceptive Advisors held 170 positions worth $3.57B, up 18% from $3.02B the previous quarter. Its ten largest holdings account for 50% of the portfolio.
Perceptive Advisors deployed $561M of net new capital in Q1 2018, opening 38 new positions and adding to 32 existing holdings. Its largest new stake was Alexion Pharmaceuticals: 873,450 shares worth $97.4M.
By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 98% a quarter earlier, followed by Consumer Staples and Consumer Discretionary.
On the sell side, the largest reduction was AnaptysBio, an estimated $58.5M trimmed.
- Perceptive Advisors's largest Q1 2018 buy was Alexion Pharmaceuticals: 873,450 shares worth $97.4M.
- Perceptive Advisors added most to Biohaven Pharmaceutical Holding Company Ltd. in Q1 2018, an estimated $79.7M increase.
- Perceptive Advisors's biggest Q1 2018 reduction was AnaptysBio, cutting an estimated $58.5M.
- Perceptive Advisors fully exited Zimmer Biomet in Q1 2018, selling an estimated $24.1M.
- Perceptive Advisors's ten largest holdings make up 50% of its $3.57B portfolio in Q1 2018.
- Perceptive Advisors opened 38 new positions and closed 33 in Q1 2018.
- Perceptive Advisors's portfolio value rose 18% quarter-over-quarter to $3.57B.
Based on Perceptive Advisors's 13F filing for Q1 2018, filed 15 May 2018.